Clinical trials: Precision Treatment
Inflammatory Bowel Disease
Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab
Infliximab (IFX) is highly effective in inducing and maintaining remission in patients with inflammatory bowel disease (IBD). However, a large proportion of patients will eventually lose response to IFX.
- Trial name
- PRECISION (NCT02453776)
- Testing
- PRECISION dosing Infliximab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hodgkin's Disease, Lymphoma, Non-Hodgkin
Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma
Radiation therapy has a well-established role in the treatment of Hodgkin's Disease and non-Hodgkin's Lymphoma. With technological developments, 3-D Dimensional (3D) planning has evolved as a highly precise treatment planning…
- Trial name
- NCT00232440
- Testing
- BodyFIX
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Solid Tumour, Haematological Malignancy
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT06988475)
- Testing
- Capmatinib
- Where
- 17 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Recurrence Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
Objectives: The purpose of this study is to evaluate the safety and efficacy of dendritic cell-precision multiple antigen T cells with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma.
- Trial name
- NCT02638857
- Testing
- TACE, Dendritic Cell, lipiodol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Military Medical University
Metastatic Melanoma
Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases
To evaluate tumor response, survival and adverse effects after precision radiotherapy (SBRT) in melanoma patients with ongoing PD-1 inhibitor treatment that have tumor progression.
- Trial name
- PROMMEL (NCT04793737)
- Testing
- Precision Radiation (SBRT)
- Where
- Sweden
- Volunteers
- 27 people
- Sponsor
- Karolinska University Hospital
Leukemia, Leukemia, Acute
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial PDT-ALL-LBL is aimed to evaluate the safety and effect of oral histone deacetylase…
- Conditions
- Leukemia, Leukemia, Acute, Adult Lymphoblastic Lymphoma, Leukemia, Lymphoblastic
- Trial name
- NCT03564704
- Testing
- Dexamethasone, vincristine, Cyclophosphamide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Refractory Solid Tumors, Next Generation Sequencing
MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors
The MyCustom study is a investigator initiated trial(IIT), prospective real-world clinical research project, a genetic biomarker-driven "basket" (tissue-type agonistic) study.
- Trial name
- NCT06030869
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tianjin Medical University Second Hospital
Type 2 DM, Type 2 DM /Diabetic Nephropathy
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
Title: Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes.
- Conditions
- Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria
- Trial name
- SIGNAL (NCT06954090)
- Testing
- Semaglutide, 1.34 mg/mL, Finerenone Oral Tablet, Dapagliflozin (DAPA)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Steno Diabetes Center Copenhagen
Smoking, Smoking Cessation
Precision Prevention Strategy to Increase Uptake and Engagement in Lung Cancer Screening and Smoking Cessation Treatment
This trial tests the effects of two versions of RiskProfile, a clinically-informed and a genetically-informed version of a patient-specific risk feedback tool, in comparison to usual care, on lung cancer screening and tobacco…
- Conditions
- Smoking, Smoking Cessation, Tobacco Use Cessation
- Trial name
- PRECISE (NCT05627674)
- Testing
- Usual Care, RiskProfile-Clin, RiskProfile-Gen
- Where
- United States
- Volunteers
- 915 people
- Sponsor
- Washington University School of Medicine
Chronic Obstructive Pulmonary Disease
Using Clinical Prediction Models to Improve Treatment for Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease of the lungs that affects more than 2.5 million Canadians. Patients with COPD experience episodes of lung attacks (or exacerbations).
- Trial name
- NCT05309356
- Testing
- ACCEPT Decision Intervention, Comparator
- Where
- 2 sites in Canada
- Volunteers
- 1,130 people
- Sponsor
- University of British Columbia
Head and Neck Neoplasms
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
The purpose of this study is to evaluate this new technology available at the University of Wisconsin Carbone Cancer Center in the setting of head and neck cancer radiation treatment planning.
- Trial name
- NCT03286972
- Testing
- PET/MRI
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Neuromuscular Diseases, Eye Diseases
Precision Diagnosis and Therapy for Rare Diseases by Interpreting Non-coding Genomes
PARADIGM study, funded by the PNRR research grant, will focus on Eye Diseases (ED) and Neuro-Muscular Diseases (NMD) as groups of genetically heterogeneous diseases which are extensively studied by the Partners partecipating in…
- Conditions
- Neuromuscular Diseases, Eye Diseases, Genetic Disease
- Trial name
- NCT06775561
- Testing
- PARADIGM study aims to streamline the process from genomic characterization of RGD patients with ED/NMD to identification of the suitable personalized therapy.
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
General Mental Health and Well-Being, Mental Disorders
PREWELL Digital Well-being Promotion Intervention With the BitHabit App
Mental wellbeing is a major public health concern, and digital interventions have emerged as a scalable approach for promoting mental well-being and healthy lifestyle behaviors.
- Conditions
- General Mental Health and Well-Being, Mental Disorders, Common Mental Disorders (CMD)
- Trial name
- PREWELL (NCT07868146)
- Testing
- Digital wellbeing promoting intervention with the BitHabit app
- Where
- Finland
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Epilepsy
Precision Radiation Treatment for Epilepsy (PRECISION)
The PRECISION-study offers a non-invasive, curative intervention for drug-resistant localised epilepsy patients who are not eligible for surgery.
- Trial name
- PRECISION (NCT05182437)
- Testing
- LINAC-based Stereotactic Radiotherapy
- Where
- Netherlands
- Volunteers
- 94 people
- Sponsor
- Maastricht Radiation Oncology
Advanced Solid Tumors, Metastatic Solid Tumors
Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors
Study Overview This study evaluates a proteogenomic screening platform to identify precise therapeutic targets for patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors, Locally Advanced Solid Tumors, Recurrent Solid Tumors
- Trial name
- K-PRECISION (NCT07891169)
- Testing
- Homologous Recombination Deficiency (HRD), ALK/ROS1/MET, standard care treatment
- Where
- 2 sites in South Korea
- Volunteers
- 2,800 people
- Sponsor
- National Cancer Center, Korea
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Metastatic Colorectal Cancer, BRAF V600E Mutation
Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
This study prospectively investigates the molecular mechanisms of primary and acquired resistance to standard-of-care BRAF V600E-directed therapy in patients with metastatic colorectal cancer and aims to pre-clinically develop…
- Trial name
- PARTACER (NCT07617610)
- Testing
- Longitudinal translational sampling
- Where
- 13 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Swiss Cancer Institute
Lymphoma, Non-Hodgkin, Multiple Myeloma
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a…
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Trial name
- TAPUR (NCT02693535)
- Testing
- Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Where
- 181 sites in United States, Puerto Rico
- Volunteers
- 4,200 people
- Sponsor
- American Society of Clinical Oncology
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK